GleamWall
中文EN

SPRY ARS Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671858 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-14.5%
TTM net income YoY-149.7%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR1,496.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-161.5%
Net margin-163.6%
FCF margin-149.9%
EBITDA margin-160.2%

Returns

ROE-294.6%
ROA-64.0%
ROIC (approx.)-116.0%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio3.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$37.71M$33.66M$22.68M$28.09M$32.50M$15.72M$7.97M$86.58M
R&D expense$18.26M$4.70M$4.34M$3.44M$2.75M$4.04M$2.95M$3.03M
SG&A expense$43.52M$77.58M$72.20M$59.95M$74.75M$54.31M$41.10M$35.49M
Operating income-$34.17M-$61.47M-$60.15M-$41.47M-$53.19M-$47.61M-$37.18M$47.20M
Net income-$35.59M-$62.34M-$60.62M-$41.32M-$51.15M-$44.88M-$33.94M$49.93M
EBITDA-$33.76M-$61.05M-$59.75M-$41.05M-$52.80M-$47.34M-$36.90M$47.23M
EPS (basic)-0.36-0.63-0.61—-0.52-0.46-0.35—
EPS (diluted)-0.36-0.63-0.61—-0.52-0.46-0.35—
Weighted avg. shares (diluted)99.69M99.31M99.30M—98.81M98.36M98.06M—
Balance sheet
Cash & equivalents$25.62M$8.16M$24.32M$41.32M$59.56M$51.54M$39.86M$50.82M
Short-term investments$112.73M$135.68M$176.65M$203.67M$228.65M$188.59M$235.86M$263.20M
Receivables$52.76M$46.84M$28.66M$25.35M$36.45M$25.13M$9.30M$8.18M
Inventory$33.43M$30.73M$32.04M$31.42M$21.43M$22.11M$7.27M$10.52M
Current assets$211.03M$211.51M$245.24M$284.90M$338.86M$281.44M$303.86M$334.30M
PP&E, net$1.93M$2.08M$2.29M$2.46M$1.21M$1.07M$1.07M$1.07M
Intangibles$13.62M$13.90M$14.18M$14.45M$14.73M$12.97M$7.24M$7.37M
Total assets$251.48M$249.50M$287.57M$327.65M$372.80M$313.47M$327.32M$351.15M
Current liabilities$64.90M$60.86M$49.61M$39.15M$50.88M$45.60M$27.62M$23.44M
Long-term debt$121.81M$96.68M$96.52M$96.37M$96.23M——$0
Total debt$121.81M$96.68M$96.52M$96.37M$96.23M——$0
Total liabilities$263.44M$236.98M$226.26M$213.39M$225.15M$121.15M$98.34M$94.36M
Shareholders' equity-$11.96M$12.51M$61.31M$114.26M$147.66M$192.32M$228.97M$256.80M
Net debt$96.19M$88.51M$72.20M$55.06M$36.67M——-$50.82M
Shares outstanding100.25M99.44M99.30M99.29M98.84M98.70M98.13M97.95M
Cash flow statement
Operating cash flow-$33.71M-$60.93M-$44.95M-$43.48M-$47.05M-$39.59M-$40.74M$42.00M
Capital expenditure$0$0$0$0$197,000$51,000$91,000$302,000
Free cash flow-$33.71M-$60.93M-$44.95M-$43.48M-$47.24M-$39.64M-$40.83M$41.70M
Investing cash flow$23.41M$41.57M$27.79M$24.11M-$44.98M$48.57M$29.06M-$101.76M
Financing cash flow$27.76M$3.20M$159,000$1.13M$100.05M$2.70M$725,000$70.92M
Depreciation & amortization$415,000$416,000$397,000$417,000$391,000$279,000$280,000$29,000
Stock-based compensation$8.12M$12.39M$7.42M$5.74M$5.69M$5.37M$5.30M$4.26M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.